These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37674872)

  • 21. Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
    Sengupta AK; Gunda A; Malpani S; Serkad CPV; Basavaraj C; Bapat A; Bakre MM
    Cancer Med; 2020 Nov; 9(21):7810-7818. PubMed ID: 33027559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.
    Gage MM; Rosman M; Mylander WC; Giblin E; Kim HS; Cope L; Umbricht C; Wolff AC; Tafra L
    Clin Breast Cancer; 2015 Dec; 15(6):467-72. PubMed ID: 26072275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
    Kwon MJ; Lee JE; Jeong J; Woo SU; Han J; Kang BI; Kim JE; Moon Y; Lee SB; Lee S; Choi YL; Kwon Y; Song K; Gong G; Shin YK
    Front Oncol; 2019; 9():667. PubMed ID: 31404265
    [No Abstract]   [Full Text] [Related]  

  • 25. Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score.
    Al-Zawi ASA; Yin SL; Aladili Z
    Contemp Oncol (Pozn); 2022; 26(2):139-143. PubMed ID: 35903213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx.
    Chiru ED; Oseledchyk A; Schoetzau A; Kurzeder C; Mosimann R; Vetter M; Grašič Kuhar C
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning.
    Kim I; Choi HJ; Ryu JM; Lee SK; Yu JH; Kim SW; Nam SJ; Lee JE
    Eur J Surg Oncol; 2019 Feb; 45(2):134-140. PubMed ID: 30348602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
    Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
    Walter VP; Taran FA; Wallwiener M; Bauer A; Grischke EM; Walter CB; Hahn M; Brucker SY; Hartkopf AD
    Geburtshilfe Frauenheilkd; 2020 Jun; 80(6):619-627. PubMed ID: 32565552
    [No Abstract]   [Full Text] [Related]  

  • 32. Young Age as a Predictor of Chemotherapy Recommendation and Treatment in Breast Cancer: A National Cancer Database Study.
    Graham E; Bennett K; Boselli D; Hecksher A; Schepel C; White RL; Hadzikadic-Gusic L
    J Surg Res; 2024 Apr; 296():155-164. PubMed ID: 38277952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    Whitney J; Corredor G; Janowczyk A; Ganesan S; Doyle S; Tomaszewski J; Feldman M; Gilmore H; Madabhushi A
    BMC Cancer; 2018 May; 18(1):610. PubMed ID: 29848291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients.
    Onoda T; Yamauchi H; Yagata H; Tsugawa K; Hayashi N; Yoshida A; Suzuki K; Sakurai O; Nakamura S
    Breast Cancer; 2015 Jul; 22(4):406-12. PubMed ID: 24081457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
    Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
    Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
    Rizki H; Hillyar C; Abbassi O; Miles-Dua S
    Cureus; 2020 Mar; 12(3):e7269. PubMed ID: 32195072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer.
    Song R; Lee DE; Lee EG; Lee S; Kang HS; Han JH; Lee KS; Sim SH; Chae H; Kwon Y; Woo J; Jung SY
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
    Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
    Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
    Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
    Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.